IM Cannabis (IMCC) Competitors $2.25 +0.04 (+1.81%) Closing price 02/14/2025 03:48 PM EasternExtended Trading$2.25 0.00 (0.00%) As of 02/14/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends IMCC vs. INAB, APRE, OKUR, SNTI, MIRA, LPCN, BCAB, MEIP, MRKR, and CARMShould you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include IN8bio (INAB), Aprea Therapeutics (APRE), OnKure Therapeutics (OKUR), Senti Biosciences (SNTI), MIRA Pharmaceuticals (MIRA), Lipocine (LPCN), BioAtla (BCAB), MEI Pharma (MEIP), Marker Therapeutics (MRKR), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical products" industry. IM Cannabis vs. IN8bio Aprea Therapeutics OnKure Therapeutics Senti Biosciences MIRA Pharmaceuticals Lipocine BioAtla MEI Pharma Marker Therapeutics Carisma Therapeutics IM Cannabis (NASDAQ:IMCC) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation. Is IMCC or INAB more profitable? IN8bio has a net margin of 0.00% compared to IM Cannabis' net margin of -25.55%. IM Cannabis' return on equity of -129.86% beat IN8bio's return on equity.Company Net Margins Return on Equity Return on Assets IM Cannabis-25.55% -129.86% -23.63% IN8bio N/A -197.15%-130.48% Do analysts rate IMCC or INAB? IN8bio has a consensus price target of $7.75, indicating a potential upside of 2,565.06%. Given IN8bio's stronger consensus rating and higher probable upside, analysts plainly believe IN8bio is more favorable than IM Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00IN8bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in IMCC or INAB? 7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 5.9% of IM Cannabis shares are owned by insiders. Comparatively, 15.5% of IN8bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation and earnings, IMCC or INAB? IM Cannabis has higher revenue and earnings than IN8bio. IM Cannabis is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIM Cannabis$36.15M0.14-$7.04M-$3.41-0.66IN8bioN/AN/A-$30.01M-$0.75-0.39 Does the media favor IMCC or INAB? In the previous week, IN8bio had 16 more articles in the media than IM Cannabis. MarketBeat recorded 17 mentions for IN8bio and 1 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 1.00 beat IN8bio's score of 0.49 indicating that IM Cannabis is being referred to more favorably in the media. Company Overall Sentiment IM Cannabis Positive IN8bio Neutral Does the MarketBeat Community prefer IMCC or INAB? IN8bio received 19 more outperform votes than IM Cannabis when rated by MarketBeat users. Likewise, 73.53% of users gave IN8bio an outperform vote while only 42.86% of users gave IM Cannabis an outperform vote. CompanyUnderperformOutperformIM CannabisOutperform Votes642.86% Underperform Votes857.14% IN8bioOutperform Votes2573.53% Underperform Votes926.47% Which has more volatility & risk, IMCC or INAB? IM Cannabis has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. SummaryIN8bio beats IM Cannabis on 11 of the 17 factors compared between the two stocks. Get IM Cannabis News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCC vs. The Competition Export to ExcelMetricIM CannabisMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.05M$1.21B$5.84B$9.14BDividend YieldN/AN/A5.27%4.00%P/E Ratio-0.6639.6026.2019.39Price / Sales0.145.69468.35124.16Price / CashN/A10.8846.1438.90Price / Book0.491.917.275.05Net Income-$7.04M-$53.22M$3.19B$222.74M7 Day Performance-0.22%1.51%2.82%2.11%1 Month Performance-7.41%3.23%4.59%2.33%1 Year Performance27.33%-6.57%22.54%16.79% IM Cannabis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCCIM Cannabis1.2093 of 5 stars$2.25+1.8%N/A+25.0%$5.05M$36.15M-0.66340Short Interest ↓Positive NewsINABIN8bio3.8728 of 5 stars$0.27+3.9%$7.75+2,769.3%-74.0%$19.58MN/A-0.3620Analyst ForecastShort Interest ↓News CoverageGap DownAPREAprea Therapeutics2.4374 of 5 stars$3.59-6.3%$15.50+331.8%-40.1%$19.49M$580,000.00-1.287Short Interest ↑OKUROnKure Therapeutics3.3927 of 5 stars$5.82-0.5%$36.00+518.6%N/A$19.44MN/A-0.48N/AGap UpSNTISenti Biosciences2.6695 of 5 stars$4.02-3.1%$10.00+148.8%+4.3%$19.38M$2.56M-0.264Short Interest ↑Negative NewsMIRAMIRA Pharmaceuticals2.5104 of 5 stars$1.17+1.7%$14.00+1,096.6%+0.0%$19.38MN/A-2.092LPCNLipocine2.0853 of 5 stars$3.50flat$10.00+185.7%-11.2%$18.73M$500,000.00-4.6110Short Interest ↑News CoverageBCABBioAtla3.5138 of 5 stars$0.38-14.4%$6.00+1,461.3%-81.8%$18.58MN/A-0.2360Short Interest ↓MEIPMEI Pharma4.5491 of 5 stars$2.77-0.4%$7.00+152.7%-42.9%$18.45M$65.30M-0.40100Earnings ReportAnalyst ForecastShort Interest ↓Gap DownMRKRMarker Therapeutics4.38 of 5 stars$1.72-2.8%$19.00+1,004.7%-57.8%$18.42M$3.31M0.0060Short Interest ↑Analyst RevisionNews CoverageCARMCarisma Therapeutics3.408 of 5 stars$0.44-5.2%$4.94+1,027.3%-76.9%$18.30M$14.92M-0.2820Short Interest ↑Negative NewsGap Down Related Companies and Tools Related Companies INAB Competitors APRE Competitors OKUR Competitors SNTI Competitors MIRA Competitors LPCN Competitors BCAB Competitors MEIP Competitors MRKR Competitors CARM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMCC) was last updated on 2/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IM Cannabis Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share IM Cannabis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.